Follow Nurix Therapeutics to never miss an important update.
H.C. Wainwright raised its price target for the stock to $36 from $34. Several other firms also adjusted their outlooks this week, bringing the average analyst target to $36. These moves follow a quarter where the company secured a massive payment from a partner, which significantly strengthened its cash position to $1.1 billion. While these target tweaks are routine, they reflect growing confidence in the company's ability to fund its drug trials through 2029.
Source: H.C. Wainwright
The company reported revenue of $670 million, far higher than the $20 million analysts expected. This spike came from a $700 million upfront payment from Roche to use the company's technology for destroying disease-causing proteins. This cash infusion leaves the company with $1.1 billion in the bank, which management says is enough to fund its drug development into late 2029.
While the financial results were skewed by this one-time gain, the real progress is in the clinic. The company began dosing the first patient in a final-stage Phase 3 trial for its lead drug, bexobrutideg, to treat a type of blood cancer. This trial is the most important hurdle for the business, as success would prove its technology can outperform current standard treatments and open a multi-billion dollar market.
See the full quarter, and how our tracked metrics did
Source: 8-K filing
The first patient has been enrolled in a study testing bexobrutideg in combination with venetoclax, a common treatment for blood cancer. This trial aims to see if using the two drugs together is more effective for patients whose cancer has returned after previous treatments. If successful, this combination strategy could make the company's drug a more versatile tool for doctors and increase the number of patients who can use it.
Source: GlobeNewsWire
Gilead Sciences extended its research agreement with the company for another two years to continue finding new cancer treatments. This extension builds on a relationship that started in 2019 and allows the company to keep a 50 percent share of any profits for certain programs in the U.S. Having a major pharmaceutical firm commit more time to the partnership validates the technology and provides a steady path for developing new drugs without the company bearing all the costs alone.
Source: GlobeNewsWire
The company earned $7 million from Pfizer after reaching a research milestone in their joint effort to develop a new class of cancer-fighting molecules. While the dollar amount is small compared to the company's total cash, it shows that its collaborations with big pharmaceutical firms are making steady technical progress. These payments help offset the high costs of running a biotech business while the company works toward getting its first drug approved for sale.
Source: GlobeNewsWire
Management has a history of missing its own targets, but a massive one-time payment from Roche just provided enough cash to fund the business for three years.
| Expectation | |
|---|---|
| EPS | $-0.46 |
| Revenue | $38M |
Follow Nurix Therapeutics to get the latest and most important updates.
Follow NRIX